Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
Plasma cholesterol and triglyceride (TG) levels are twice as high in hibernating brown bears (Ursus arctos) than healthy humans. Yet, bears display no signs of early stage atherosclerosis development when adult. To explore this apparent paradox, we analyzed plasma lipoproteins from the same 10 bears...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S002222752100047X |
id |
doaj-d0067720a8574924b204b6fa6db396c8 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matteo Pedrelli Paolo Parini Jonas Kindberg Jon M. Arnemo Ingemar Bjorkhem Ulrika Aasa Maria Westerståhl Anna Walentinsson Chiara Pavanello Marta Turri Laura Calabresi Katariina Öörni Gérman Camejo Ole Fröbert Eva Hurt-Camejo |
spellingShingle |
Matteo Pedrelli Paolo Parini Jonas Kindberg Jon M. Arnemo Ingemar Bjorkhem Ulrika Aasa Maria Westerståhl Anna Walentinsson Chiara Pavanello Marta Turri Laura Calabresi Katariina Öörni Gérman Camejo Ole Fröbert Eva Hurt-Camejo Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) Journal of Lipid Research Ursus arctos hibernation lipids apoB lipoproteins proteoglycans |
author_facet |
Matteo Pedrelli Paolo Parini Jonas Kindberg Jon M. Arnemo Ingemar Bjorkhem Ulrika Aasa Maria Westerståhl Anna Walentinsson Chiara Pavanello Marta Turri Laura Calabresi Katariina Öörni Gérman Camejo Ole Fröbert Eva Hurt-Camejo |
author_sort |
Matteo Pedrelli |
title |
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) |
title_short |
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) |
title_full |
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) |
title_fullStr |
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) |
title_full_unstemmed |
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) |
title_sort |
vasculoprotective properties of plasma lipoproteins from brown bears (ursus arctos) |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2021-01-01 |
description |
Plasma cholesterol and triglyceride (TG) levels are twice as high in hibernating brown bears (Ursus arctos) than healthy humans. Yet, bears display no signs of early stage atherosclerosis development when adult. To explore this apparent paradox, we analyzed plasma lipoproteins from the same 10 bears in winter (hibernation) and summer using size exclusion chromatography, ultracentrifugation, and electrophoresis. LDL binding to arterial proteoglycans (PGs) and plasma cholesterol efflux capacity (CEC) were also evaluated. The data collected and analyzed from bears were also compared with those from healthy humans. In bears, the cholesterol ester, unesterified cholesterol, TG, and phospholipid contents of VLDL and LDL were higher in winter than in summer. The percentage lipid composition of LDL differed between bears and humans but did not change seasonally in bears. Bear LDL was larger, richer in TGs, showed prebeta electrophoretic mobility, and had 5–10 times lower binding to arterial PGs than human LDL. Finally, plasma CEC was higher in bears than in humans, especially the HDL fraction when mediated by ABCA1. These results suggest that in brown bears the absence of early atherogenesis is likely associated with a lower affinity of LDL for arterial PGs and an elevated CEC of bear plasma. |
topic |
Ursus arctos hibernation lipids apoB lipoproteins proteoglycans |
url |
http://www.sciencedirect.com/science/article/pii/S002222752100047X |
work_keys_str_mv |
AT matteopedrelli vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT paoloparini vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT jonaskindberg vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT jonmarnemo vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT ingemarbjorkhem vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT ulrikaaasa vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT mariawesterstahl vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT annawalentinsson vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT chiarapavanello vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT martaturri vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT lauracalabresi vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT katariinaoorni vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT germancamejo vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT olefrobert vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos AT evahurtcamejo vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos |
_version_ |
1721443564873842688 |
spelling |
doaj-d0067720a8574924b204b6fa6db396c82021-05-12T04:09:26ZengElsevierJournal of Lipid Research0022-22752021-01-0162100065Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)Matteo Pedrelli0Paolo Parini1Jonas Kindberg2Jon M. Arnemo3Ingemar Bjorkhem4Ulrika Aasa5Maria Westerståhl6Anna Walentinsson7Chiara Pavanello8Marta Turri9Laura Calabresi10Katariina Öörni11Gérman Camejo12Ole Fröbert13Eva Hurt-Camejo14Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; For correspondence: Eva Hurt-Camejo; Matteo PedrelliDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Metabolism Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Theme Inflammation and Infection, Karolinska university Hospital, Stockholm, SwedenNorwegian Institute for Nature Research, Trondheim, Norway; Swedish University of Agricultural Sciences, Department of Wildlife, Fish, and Environmental Studies, Umeå, SwedenSwedish University of Agricultural Sciences, Department of Wildlife, Fish, and Environmental Studies, Umeå, Sweden; Department of Forestry and Wildlife Management, Inland Norway University of Applied Sciences, Campus Evenstad, Koppang, NorwayDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenDepartment of Community Medicine and Rehabilitation, Umeå University, Umeå, SwedenDivision of Clinical Physiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenTranslational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenCentro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyCentro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyCentro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyAtherosclerosis Research Laboratory, Wihuri Research Institute, Helsinki, FinlandDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenSwedish University of Agricultural Sciences, Department of Wildlife, Fish, and Environmental Studies, Umeå, Sweden; Örebro University, Faculty of Health, Department of Cardiology, Örebro, SwedenDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; For correspondence: Eva Hurt-Camejo; Matteo PedrelliPlasma cholesterol and triglyceride (TG) levels are twice as high in hibernating brown bears (Ursus arctos) than healthy humans. Yet, bears display no signs of early stage atherosclerosis development when adult. To explore this apparent paradox, we analyzed plasma lipoproteins from the same 10 bears in winter (hibernation) and summer using size exclusion chromatography, ultracentrifugation, and electrophoresis. LDL binding to arterial proteoglycans (PGs) and plasma cholesterol efflux capacity (CEC) were also evaluated. The data collected and analyzed from bears were also compared with those from healthy humans. In bears, the cholesterol ester, unesterified cholesterol, TG, and phospholipid contents of VLDL and LDL were higher in winter than in summer. The percentage lipid composition of LDL differed between bears and humans but did not change seasonally in bears. Bear LDL was larger, richer in TGs, showed prebeta electrophoretic mobility, and had 5–10 times lower binding to arterial PGs than human LDL. Finally, plasma CEC was higher in bears than in humans, especially the HDL fraction when mediated by ABCA1. These results suggest that in brown bears the absence of early atherogenesis is likely associated with a lower affinity of LDL for arterial PGs and an elevated CEC of bear plasma.http://www.sciencedirect.com/science/article/pii/S002222752100047XUrsus arctoshibernationlipidsapoBlipoproteinsproteoglycans |